BECTON DICKINSON MEDICAL SYSTEMS 3 ML BD¿ PRE-FILLED NORMAL SALINE SYRINGE, IN 3 ML SYRINGE; PREFILLED SALINE FLUSH SYRINGE
|
Back to Search Results |
|
Catalog Number 306507 |
Device Problems
Nonstandard Device (1420); Microbial Contamination of Device (2303)
|
Patient Problem
Unspecified Infection (1930)
|
Event Date 03/14/2018 |
Event Type
Injury
|
Manufacturer Narrative
|
Medical device expiration date: unknown.Fda notified?: the fda was made aware of this incident via voluntary medwatch 5076820.This information was communicated to bd on 5/8/2018 by the fda.A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.Device manufacture date: unknown.
|
|
Event Description
|
It was reported that a patient with multiple anomalies status post cardiac surgery had positive peripheral blood cultures for serratia marcescens.The patient was hospitalized, received an positive echo, and is a presumed serratia endocarditis.The device implicated with this incident is a 3 ml bd¿ pre-filled normal saline syringe, in 3 ml syringe.The facility where this event occurred removed this product.*out of an abundance of caution and in the interest of public health, bd voluntarily recalled certain lots of bd posiflush¿ heparin lock flush and bd¿ pre-filled normal saline flush syringes due to a potential for contamination with serratia marcescens bacterium.Bd was notified by the u.S.Food and drug administration (fda) and centers for disease control and prevention (cdc) about a potential epidemiological link between catheter related blood stream infections and the s.Marcescens bacterium.Specifically, the fda and cdc identified a potential connection between reports of infection in a small number of patients caused by s.Marcescens across multiple states.Cdc¿s initial investigation found that affected patients had received treatment using certain bd flush products.To date, there is no evidence of bd flush product testing positive for this bacterium.Investigations are ongoing by bd, fda, and cdc.
|
|
Manufacturer Narrative
|
H.6.Investigation summary: as both a lot number and sample were unavailable for this incident, a full investigation consisting of a sample analysis and a device history record review could not be completed.Prior to april 2018, there was no trend for infection regarding the bd franklin products.Upon the increase of infection reports beginning in april 2018, a corrective and preventive action plan was initiated to address the issue.A review of all lot sterility testing performed for product released between april 2015 and may 2018 confirmed that no organism growth was identified for any lots released during the shelf life of this product.A direct causation between the reported infections and the bd franklin product has not been identified.Investigation conclusion: unknown ¿ lot number was not provided.Prior to the report of infection evaluated in mps-18-1248-sa, there was no trend for infection cases reported for franklin product.This complaint is part of a new trend which began in april 2018.(b)(4) was initiated to address this issue.As no lot number was provided, a dhr review could not be completed.Quantity of retained samples used for testing: 0 ¿ although retain samples are available for all lots manufactured in franklin, as the lot number was not provided, retain samples were not tested.A review of all lot sterility testing performed for product released between april 2015 & may 2018 confirmed that no organism growth was identified for any lots released during the shelf-life of this product.Conclusion(s): the root cause analysis of the reported infection cases under (b)(4) has not identified a direct causation between the infections and the bd franklin product.
|
|
Search Alerts/Recalls
|
|
|